Lexeo Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 30, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 30, 2026
LXEO$3.14+8.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
(In thousands)
| Years Ended December 31, | ||||
|---|---|---|---|---|
| 2025 · 2024 | ||||
| Cash flows from operating activities: | ||||
| Net loss | $(99,961) | $(98,333) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Reduction in the carrying amount of ROU assets, operating | 1,491 | 1,373 | ||
| Reduction in the carrying amount of ROU assets, finance | 320 | 325 | ||
| Stock-based compensation expense | 12,132 | 12,474 | ||
| Depreciation and amortization expense | 268 | 304 | ||
| Non-cash gain on long-term investment | (3,390) | - | ||
| Net realized gain on investments in U.S. Treasury securities | (17) | - | ||
| Amortization of premium (accretion of discount) on investments in U.S. Treasury securities | 111 | (23) | ||
| Changes in operating assets and liabilities: | ||||
| Prepaid expenses and other current assets | (2,004) | (1,690) | ||
| Accounts payable | (1,561) | 2,378 | ||
| Accrued expenses and other current liabilities | (4,445) | 3,367 | ||
| Lease liabilities, operating | (1,496) | (1,336) | ||
| Lease liabilities, finance | (9) | 10 | ||
| Net cash used in operating activities | (98,561) | (81,151) | ||
| Cash flows from investing activities: | ||||
| Purchase of property and equipment | (397) | (481) | ||
| Purchases of investments | (195,382) | (93,596) | ||
| Proceeds from sales or maturities of investments | 105,527 | - | ||
| Net cash used in investing activities | (90,252) | (94,077) | ||
| Cash flows from financing activities: | ||||
| Proceeds from exercise of stock options | 59 | 491 | ||
| Payments on finance leases | (533) | (410) | ||
| Proceeds from common stock issuances under 2023 ESPP | 270 | - | ||
| Treasury stock repurchase | - | (17) | ||
| Proceeds from issuance of common stock upon March 2024 Private Placement | - | 94,999 | ||
| Third-party commissions and offering costs incurred upon March 2024 Private Placement | - | (6,287) | ||
| Proceeds from issuance of common stock, pre-funded warrants and warrants to purchase common stock upon May 2025 Private Placement | 79,999 | - | ||
| Third-party commissions and offering costs incurred upon May 2025 Private Placement | (6,917) | - | ||
| Proceeds from issuance of common stock and pre-funded warrants to purchase common stock upon October 2025 Financing Transactions | 153,750 | - | ||
| Third-party commissions and offering costs incurred upon October 2025 Financing Transactions | (9,833) | - | ||
| Net cash provided by financing activities | 216,795 | 88,776 | ||
| Net change in cash, cash equivalents and restricted cash | 27,982 | (86,452) | ||
| Cash, cash equivalents and restricted cash at beginning of period | 38,266 | 124,718 | ||
| Cash, cash equivalents and restricted cash at end of period | $66,248 | $38,266 | ||
| Supplemental disclosures of cash flow information | ||||
| Interest paid | $104 | $127 | ||
| Supplemental disclosure of non-cash activities | ||||
| Unrealized gain (loss) on investments | $291 | $(103) | ||
| Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase, net of proceeds received from early exercise of unvested stock options subject to repurchase and recorded as deposit liabilities | $37 | $59 | ||
| Unpaid offering costs included in accounts payable and accrued expenses | $25 | $ | - | |
| Reclassifications from property and equipment to prepaid expenses and other current assets | $18 | $98 | ||
| Finance lease right-of use assets and finance lease liabilities recognized | $ | - | $22 | |
| Property and equipment purchased in the prior period and paid in the current period, net of property and equipment purchased in the current period included in accounts payable | $ | - | $(120) | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.